ERBB2 and breast cancer: SG was approved by the FDA in February 2023 with the following indication: unresectable locally advanced HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH−) BC patients who received endocrine-based therapy and at least other two systemic treatments for metastatic disease [44].